Eli Lilly's phase 3 SURMOUNT-OSA trials show tirzepatide injection significantly reduces apnea events in adults with obesit...

In the primary endpoint, tirzepatide reduced moderate-to-severe OSA severity by up to 62.8% (about 30 fewer events per hour)In ...

https://www.statnews.com/2024/06/21/medicare-coverage-wegovy-weight-loss-cancer-blood-tests-grail/

Gilead Sciences faces Wall Street speculation about its potential in the obesity drug market despite its focus on liver treatme...

As per the official press release, the 16-week trial aimed to evaluate the safety, tolerability, and clinical effects of the dr...

Nestle's new Vital Pursuit brand targets individuals on weight-loss drugs without mentioning medications on packaging, addr...

Evotec consults defense advisers following a significant share price decline, raising concerns about a potential takeover.

Cantor Fitzgerald analyst Louise Chen reiterates Eli Lilly and Co (NYSE:LLY) with a Overweight and maintains $885 price target.

Eli Lilly & Co has intensified its fight against counterfeit versions of its popular obesity drug, Zepbound, by initiating ...